Due to the poor prognosis for another hormone receptor-HER2 positive BC the new therapies targeting HER-2 are under evaluation, e.g., treatment with the monoclonal antibody trastuzumab (herceptin) directed against the extracellular domain IV of HER2 [191]. The gene discussed is ERBB2; the disease is breast cancer.